Evidence map›Paper›PMID 36428527›Full record

ReviewBiomedicines2022

Cell-Free Amniotic Fluid and Regenerative Medicine: Current Applications and Future Opportunities.

Charles M Bowen, Frederick S Ditmars, Ashim Gupta, Jo-Anna Reems, William Samuel Fagg

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Amniotic fluid: its role in fetal development and beyond.Journal of perinatology : official journal of the California Perinatal Association · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Solving STODS-Surgical Temporary Ocular Discomfort Syndrome.Diagnostics (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Charles M BowenDepartment of Surgery, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.ORCID 0000-0001-5400-4304
Frederick S DitmarsDepartment of Surgery, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Ashim GuptaFuture Biologics, Lawrenceville, GA 30043, USA.ORCID 0000-0003-1224-2755
Jo-Anna ReemsMerakris Therapeutics, RTP Frontier 800 Park Offices Dr. Suite 3322, Research Triangle Park, NC 27709, USA.
William Samuel FaggDepartment of Surgery, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.ORCID 0000-0003-2909-1666
Institute of Cytology and Preventive Oncology · INThe University of Texas Medical Branch at Galveston · USUniversity of Utah · US

Funding

Research Project 3: Role of Posttranslational Protein Modifications in the Pathogenesis of Ebola Virus DiseaseP01AI150585 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER · 2021 to 2025
$11.3M
UTMB Clinical and Translational Science AwardKL2TR001441 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI AMEREDES, BILL T · 2015 to 2024
$4.0M
NCATS NIH HHS KL2 TR001441NIAID NIH HHS P01 AI150585NIH HHS KL2TR001441
6 · The paper itself

Abstract

Amniotic fluid (AF) provides critical biological and physical support for the developing fetus. While AF is an excellent source of progenitor cells with regenerative properties, recent investigations indicate that cell-free AF (cfAF), which consists of its soluble components and extracellular vesicles, can also stimulate regenerative and reparative activities. This review summarizes published fundamental, translational, and clinical investigations into the biological activity and potential use of cfAF as a therapeutic agent. Recurring themes emerge from these studies, which indicate that cfAF can confer immunomodulatory, anti-inflammatory, and pro-growth characteristics to the target cells/tissue with which they come into contact. Another common observation is that cfAF seems to promote a return of cells/tissue to a homeostatic resting state when applied to a model of cell stress or disease. The precise mechanisms through which these effects are mediated have not been entirely defined, but it is clear that cfAF can safely and effectively treat cutaneous wounds and perhaps orthopedic degenerative conditions. Additional applications are currently being investigated, but require further study to dissect the fundamental mechanisms through which its regenerative effects are mediated. By doing so, rational design can be used to fully unlock its potential in the biotechnology lab and in the clinic.

Indexed as

amniotic fluidexosomesregenerative medicinetissue engineeringtranslational medicine

Identifiers

PMID36428527
PMCPMC9687956
OpenAlexW4309456840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.